FAQ

3'-deamino-3'-hydroxydoxorubicin

Known as: 3-DHD, 5,12-Naphthacenedione, 10-((2,6-dideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-, hydroxyrubicin 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1984-2014
012319842014

Related topics

Related topics

2 relations

Broader (2)

EpirubicinTopoisomerase II Inhibitors

Related mentions per year

Related mentions per year

1951-2018
1960198020002020
3'-deamino-3'-hydroxydoxorubicin
Epirubicin
Topoisomerase II Inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2001
2001
Drug sequestration in cytoplasmic organelles does not contribute to the diminished sensitivity of anthracyclines in multidrug resistant K562 cells.
Cells that acquire multidrug resistance (MDR) are characterized by a decreased accumulation of a variety of drugs. In addition… (More)
Is this relevant?
2000
2000
Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P.
Multidrug resistance phenotype in mammalian cells is often correlated with overexpression of P-glycoprotein or Multidrug… (More)
Is this relevant?
1997
1997
Electrostatic and non-electrostatic contributions to the binding free energies of anthracycline antibiotics to DNA.
The knowledge about molecular factors driving simple ligand-DNA interactions is still limited. The aim of the present study was… (More)
Is this relevant?
1994
1994
Overexpression of P-glycoprotein but not its mRNA in multidrug resistant cells selected with hydroxyrubicin.
Previous studies have revealed that cultured cells treated with lipophilic natural products containing aromatic rings and basic… (More)
Is this relevant?
1994
1994
Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance.
In vivo effectiveness of doxorubicin remains restricted due to toxicity and drug resistance. Hydroxyrubicin is a synthetic analog… (More)
Is this relevant?
1994
1994
P-glycoprotein-mediated efflux of hydroxyrubicin, a neutral anthracycline derivative, in resistant K562 cells.
Hydroxyrubin (OH-Dox), a neutral doxorubicin derivative that is only slightly cross-resistant to doxorubicin (Dox), can be… (More)
Is this relevant?
1993
1993
Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity.
Hydroxyrubicin, a synthetic doxorubicin analog in which the basic amino group at C-3' is replaced by a hydroxyl group, was used… (More)
Is this relevant?
1993
1993
N-benzyladriamycin-14-valerate (AD 198)-resistant cells exhibit highly selective cross-resistance to other anthracyclines that circumvent multidrug resistance.
N-Benzyladriamycin-14-valerate (AD 198)-resistant murine J774.2 macrophage-like cells (A300) exhibited a novel mechanism of… (More)
Is this relevant?
1993
1993
Intrinsic cytotoxicity and reversal of multidrug-resistance by monensin in kb parent and mdr cells.
Results presented in this study indicate that monensin, a Na+/H+ gradient ionophore, is by itself a potent inhibitor of… (More)
Is this relevant?
1984
1984
Synthesis and antitumor activity of 3'-deamino-3'-hydroxydoxorubicin. A facile procedure for the preparation of doxorubicin analogs.
Two successful routes have been developed for preparation of 3'-deamino-3'-hydroxydoxorubicin (11), based on protection of the 14… (More)
  • table 1
Is this relevant?